A molecular atlas of cell-type specific signatures in the parkinsonian striatum
By onProgressive dopamine loss in PD affects striatum cells differently. Transcriptomic analysis in mouse and human models reveals changes in neuronal and glial populations, highlighting resilient and vulnerable cell types for potential new treatments.
LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
By onPD LRRK2 influences the effects of haloperidol, a common antipsychotic, on striatal indirect pathway neurons. Inhibiting LRRK2 kinase activity reduces haloperidol’s motor side effects, suggesting a way to ease antipsychotic side effects.
Mass spectrometry proteomics dataset
By onThe mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD053892
LRRK2 kinase inhibition restores haloperidol effects on rpS6 signaling in iSPNs
By onIF images in LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
LRRK2 regulates haloperidol mediated upregulation of immediate early genes in iSPNs
By onTo define the impact of LRRK2 kinase activity on the expression pattern of Nr4a1 mRNA in the SPNs, we used multicolored single-molecule fluorescence in situ hybridization
Striatal sections immunofluorescence and analysis
By onStriatal sections immunofluorescence and analysis related to LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
Multicolor fluorescence in situ hybridization and analysis
By onMulticolor fluorescence in situ hybridization and analysis related to LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
Drugs and treatment dosing
By onDrugs and treatment dosing protocol related to LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
LC-MS/MS Analysis
By onLC-MS/MS Analysis related to LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons
Leucine-rich repeat kinase 2 impairs the release sites of Parkinson’s disease vulnerable dopamine axons
By onSynaptic dysfunctions manifest early in Parkinson's disease. Research on LRRK2 mutations, using advanced genetic models, reveals their effects on neuronal synapses, primarily impacted by the disease, offering insights into potential early therapies.
LRRK2 alters the composition and organization of active zone release sites in dopaminergic striatal synaptosomes
By onConfocal images and analysis overview
TH fibers and dopamine vesicle clustering alterations
By onTh fibers and dopamine vesicle clustering alterations in Lrrk2WT and Lrrk2G2019S mice
LRRK2 is expressed in dopamine neurons and is enriched in the vulnerable subpopulation
By onConfocal images from Leucine-rich repeat kinase 2 impairs the release sites of Parkinson’s disease vulnerable dopamine axons
LRRK2 disrupts the number and composition of active zone release sites in vulnerable dopamine axons
By onStriatal brain sections were stained with antibodies against bassoon to analyze the number and organization of active zone sites in Aldh1a1+ (EYFP+) or Aldh1a1- (mCherry+) axons from the same mouse
Immunofluorescence and confocal imaging in brain sections and image analysis
By onImmunofluorescence and confocal imaging in brain sections and image analysis for Leucine-rich repeat kinase 2 impairs the release sites of Parkinson’s disease vulnerable dopamine axons
